Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 1 AL 15

Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease

Lauterbach EC.

Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):1-7. doi: 10.1097/WAD.0b013e318214b7d0.

Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties

Papadopoulos V, Lecanu L.

J Neuroendocrinol. 2012 Jan;24(1):93-101. doi: 10.1111/j.1365-2826.2011.02167.x.

Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease

Haas C.

J Alzheimers Dis. 2012;28(2):241-81. doi: 10.3233/JAD-2011-110986.

Antioxidative strategies in cognitive impairment: a novel connection between biliverdin-reductase and statins

Schneider A, Simons M.

J Neurochem. 2012 Jan;120(1):1-3. doi: 10.1111/j.1471-4159.2011.07548.x.

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F.

Br J Clin Pharmacol. 2012 Apr;73(4):504-17. doi: 10.1111/j.1365-2125.2011.04134.x.

Tau-targeted treatment strategies in Alzheimer's disease

Götz J, Ittner A, Ittner LM.

Br J Pharmacol. 2012 Mar;165(5):1246-59. doi: 10.1111/j.1476-5381.2011.01713.x.

Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms

von Bernhardi R, Eugenín J.

Antioxid Redox Signal. 2012 May 1;16(9):974-1031. doi: 10.1089/ars.2011.4082. Epub 2012 Feb 7.

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease

Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER.

Clin Neuropharmacol. 2012 Jan-Feb;35(1):25-9. doi: 10.1097/WNF.0b013e31823a13d3.

Reviewing the role of donepezil in the treatment of Alzheimer's disease

Doody RS, Cummings JL, Farlow MR.

Curr Alzheimer Res. 2012 Sep;9(7):773-81. doi: 10.2174/156720512802455412.

Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease

Tobinick E.

Curr Alzheimer Res. 2012 Jan;9(1):99-109. doi: 10.2174/156720512799015073.

Metals in Alzheimer's disease: a systemic perspective

Squitti R.

Front Biosci (Landmark Ed). 2012 Jan 1;17(2):451-72. doi: 10.2741/3938.

Natural antioxidants in prevention and management of Alzheimer's disease

Zhao Y, Zhao B.

Front Biosci (Elite Ed). 2012 Jan 1;4(3):794-808. doi: 10.2741/419.

Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease

de la Monte SM.

Front Biosci (Elite Ed). 2012 Jan 1;4(4):1582-605. doi: 10.2741/e482.

RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease

Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX.

Front Biosci (Schol Ed). 2012 Jan 1;4(1):240-50. doi: 10.2741/s265.

Alpha, beta-and gamma-secretases in Alzheimer's disease

Epis R, Marcello E, Gardoni F, Di Luca M.

Front Biosci (Schol Ed). 2012 Jan 1;4(3):1126-50. doi: 10.2741/s322.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias